Trial Profile
Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Pituitary ACTH hypersecretion; Pituitary adenoma
- Focus Therapeutic Use
- 07 Jul 2015 New trial record